The present and future of inflammatory bowel disease treatment

Gastroenterology and Hepatology

Volumn 12, Issue 7, 2016, Pages 438-441

  Sandborn, William J ^a,b  

^a Division of Gastroenterology   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AGENTS USED IN INFLAMMATORY BOWEL DISEASE; AMG 139; AMISELIMOD; APD 334; AZATHIOPRINE; BI 655066; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; ETROLIZUMAB; FILGOTINIB; GOLIMUMAB; GS 574; GUSELKUMAB; INFLIXIMAB; LY 2525623; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MONGERSEN; OZANIMOD; TOFACITINIB; UNCLASSIFIED DRUG; UPADACITINIB; USTEKINUMAB; VEDOLIZUMAB;

BONE MARROW SUPPRESSION; CROHN DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUCED PANCREATITIS; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; INFECTION; INTESTINE FLORA; LYMPHOMA; NONHODGKIN LYMPHOMA; NOTE; OPPORTUNISTIC INFECTION; PANCREATITIS; PERSONALIZED MEDICINE; REMISSION; SKIN CANCER; STEM CELL TRANSPLANTATION; TREATMENT FAILURE; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS;

EID: 84978399780     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (6)

1. Dulai PS, Singh S, Casteele NV, Boland BS, Sandborn WJ. How will evolving future therapies and strategies change how we position the use of biologics in moderate to severely active inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(4):998-1009.
2. Khanna R, Chande N, Vermeire S, Sandborn WJ, Parker CE, Feagan BG. The next wave of biological agents for the treatment of IBD: evidence from Cochrane reviews. Inflamm Bowel Dis. 2016;22(7):1737-1743.
3. Ley K, Rivera-Nieves J, Sandborn WJ, Shattil S. Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov. 2016;15(3):173-183.
4. Sandborn WJ, Bhandari BR, Fogel R, et al. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther. 2016;44(2):157-169.
5. Sandborn WJ, Colombel JF, Ghosh S, et al. Eldelumab [anti-IP-10] induction therapy for ulcerative colitis: a randomised, placebo-controlled, phase 2b study. J Crohns Colitis. 2016;10(4):418-428.
6. Sandborn WJ, Feagan BG, Wolf DC, et al; TOUCHSTONE Study Group. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374(18):1754-1762.